SynthesisFrontiers in medicine2026
Differences in clinical features between axial psoriatic arthritis and axial spondyloarthritis: a systematic review and meta-analysis of observational studies.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Classification of axial psoriatic arthritis (ax-PsA) within existing spondyloarthritis (SpA) criteria remains unclear. To clarify this issue, we compared the clinical features of ax-PsA and axial SpA (ax-SpA). Methods: In this systematic review and meta-analysis, we searched six databases (PubMed, Web of Science, Cochrane Library, Ovid, Scopus, and Embase) and one trial registry (ClinicalTrials.gov) for studies published from inception to April 20, 2025, without language restrictions. Observational studies comparing ax-PsA and ax-SpA were included. Meta-analyses were conducted to evaluate disease activity scores, spinal function scores, inflammatory markers, and HLA-B27 positivity. Results: Fifteen studies including 2,704 patients with ax-PsA and 9,248 with ax-SpA from diverse global populations were analyzed. Meta-analysis showed no significant differences between ax-PsA and ax-SpA in the Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Functional Index, or C-reactive protein levels. However, ax-PsA was associated with significantly lower HLA-B27 positivity compared with ax-SpA (risk ratio, 0.37; 95% confidence interval [CI], 0.32-0.43; Conclusion: The marked difference in HLA-B27 positivity between ax-PsA and ax-SpA supports their distinction as separate disease entities. Similar disease activity and functional outcomes suggest shared downstream inflammatory pathways. The lower HLA-B27 positivity in ax-PsA may reflect alternative mechanisms of interleukin (IL)-23/IL-17 axis activation, with potential therapeutic implications. Clinical differentiation should incorporate HLA-B27 testing and imaging. Future research should focus on disease course variability and subgroup-specific characteristics. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251043651, identifier: CRD420251043651.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.